References
- Giancotti FG. Deregulation of cell signaling in cancer. FEBS Lett 2014;588:2558.
- Giamas G, Stebbing J, Vorgias CE, Knippschild U. Protein kinases as targets for cancer treatment. Pharmacogenomics 2007;8:1005.
- Tsai Ch J, Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol 2013;23:235.
- Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev Cancer 2009;9:28.
- Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005;12:621.
- Balzano D, Sántaguida S, Musacchio A, Villa F. A general framework for inhibitor resistance in protein kinases. Chem Biol 2011;18:966.
- Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714.
- Shaughnessy A. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 2012;345:e8346.
- Tiash S, Chowdhury EH. Growth factor receptors: promising drug targets in cancer. J Cancer Metastasis Treat 2015;1:190.
- Gazdar AF. Activating and resistance mutations of EGFR in non-small lung cancer: role in clinical respons to EGFR tyrosine kinase inhibitors. Oncogene 2009;28:S24–S31.
- Landi L, Cappuzzo F. Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res 2013;2:40.
- Wang DD, Ma L, Wong MP, et al. Contribution of EGFR and ErB-3 heterodimerization to the EGFR muatation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatment. PLoS One 2015;10:e0128360.
- Dawson JP, Berger MB, Lin CH-C, et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 2005;25:7734.
- Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2.
- Saito Y, Haendeler J, Hojo Y, et al. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001;21:6387.
- Black PC, Brown GA, Dinney CP, et al. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol 2011;185:693.
- Zhang L, Zheng Q, Yang Y, et al. Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents. Eur J Med Chem 2014;82:139.
- Ouwerkerk N, Boom J, Lugtenburg J, Raap J. Synthesis of [1´,2′,5′,2-13C4]-2′- deoxy-D-adenosine by a chemoenzymatic strategy to enable labelling of any of the 215 carbon-13 and nitrogen-15 isotopomers. Eur J Org Chem 2002;14:2356.
- Voigt B, Krug M, Schächtele C, et al. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors. Chem Med Chem 2008;3:120.
- Boyed MR. Status of the NCI preclinical antitumor drug discovery screen. Princ Pract Oncol 1989;3:1.
- Monks A, Scudiero D, Skehan P, Boyed M. Implementation of a pilot-scale, high flux anticancer drug screen utilizing disease-oriented panels of human tumor cell lines in culture. Proc Am Assoc Cancer Res 1989;30:607.
- Kuramochi T, Kakefuda A, Hiroyoshi Y, et al. Synthesis and structure-activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure. Bioorg Med Chem 2005;13:725.
- Jeong K-S, Cho YL, Chang S-Y, et al. Assembly and binding properties of osmate ester-bridged binuclear macrocycles. J Org Chem 1999;64:9459.
- Guérin O, Fischel JL, Ferrero J-M, et al. EGFR targeting in hormone-refractory prostate cancer: current appraisal and prospects for treatment. Pharmaceuticals 2010;3:2238.
- Zhang W, Peyton M, Xie Y, et al. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 2009;4:161.
- Fischel J-L, Ciccolini J, Formento P, Ferrero J-M, Milano G. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5′-deoxyuridine. Anti-Cancer Drugs 2006;17:807.